Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

Takaki Hiwasa; Hao Wang; Ken ichiro Goto; Seiichiro Mine; Toshio Machida; Eiichi Kobayashi; Yoichi Yoshida; Akihiko Adachi; Tomoo Matsutani; Mizuki Sata; Kazumasa Yamagishi; Hiroyasu Iso; Norie Sawada; Shoichiro Tsugane; Mitoshi Kunimatsu; Ikuo Kamitsukasa; Masahiro Mori; Kazuo Sugimoto; Akiyuki Uzawa; Mayumi Muto; Satoshi Kuwabara; Yoshio Kobayashi; Mikiko Ohno; Eiichiro Nishi; Akiko Hattori; Masashi Yamamoto; Yoshiro Maezawa; Kazuki Kobayashi; Ryoichi Ishibashi; Minoru Takemoto; Koutaro Yokote; Hirotaka Takizawa; Takashi Kishimoto; Kazuyuki Matsushita; Sohei Kobayashi; Fumio Nomura; Takahiro Arasawa; Akiko Kagaya; Tetsuro Maruyama; Hisahiro Matsubara; Minako Tomiita; Shinsaku Hamanaka; Yushi Imai; Tomoo Nakagawa; Naoya Kato; Jiro Terada; Takuma Matsumura; Yusuke Katsumata; Akira Naito; Nobuhiro Tanabe; Seiichiro Sakao; Koichiro Tatsumi; Masaaki Ito; Fumiaki Shiratori; Makoto Sumazaki; Satoshi Yajima; Hideaki Shimada; Mikako Shirouzu; Shigeyuki Yokoyama; Takashi Kudo; Hirofumi Doi; Katsuro Iwase; Hiromi Ashino; Shu Yang Li; Masaaki Kubota; Go Tomiyoshi; Natsuko Shinmen; Rika Nakamura; Hideyuki Kuroda; Yasuo Iwadate

doi:10.1186/s12916-021-02001-9

Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

Takaki Hiwasa, Hao Wang, Ken ichiro Goto, Seiichiro Mine, Toshio Machida, Eiichi Kobayashi, Yoichi Yoshida, Akihiko Adachi, Tomoo Matsutani, Mizuki Sata, Kazumasa Yamagishi, Hiroyasu Iso, Norie Sawada, Shoichiro Tsugane, Mitoshi Kunimatsu, Ikuo Kamitsukasa, Masahiro Mori, Kazuo Sugimoto, Akiyuki Uzawa, Mayumi MutoSatoshi Kuwabara, Yoshio Kobayashi, Mikiko Ohno, Eiichiro Nishi, Akiko Hattori, Masashi Yamamoto, Yoshiro Maezawa, Kazuki Kobayashi, Ryoichi Ishibashi, Minoru Takemoto, Koutaro Yokote, Hirotaka Takizawa, Takashi Kishimoto, Kazuyuki Matsushita, Sohei Kobayashi, Fumio Nomura, Takahiro Arasawa, Akiko Kagaya, Tetsuro Maruyama, Hisahiro Matsubara, Minako Tomiita, Shinsaku Hamanaka, Yushi Imai, Tomoo Nakagawa, Naoya Kato, Jiro Terada, Takuma Matsumura, Yusuke Katsumata, Akira Naito, Nobuhiro Tanabe, Seiichiro Sakao, Koichiro Tatsumi, Masaaki Ito, Fumiaki Shiratori, Makoto Sumazaki, Satoshi Yajima, Hideaki Shimada, Mikako Shirouzu, Shigeyuki Yokoyama, Takashi Kudo, Hirofumi Doi, Katsuro Iwase, Hiromi Ashino, Shu Yang Li, Masaaki Kubota, Go Tomiyoshi, Natsuko Shinmen, Rika Nakamura, Hideyuki Kuroda, Yasuo Iwadate

衛生学公衆衛生学

研究成果: Article › 査読

10 被引用数 (Scopus)

抄録

Background: Acute ischemic stroke (AIS) is a serious cause of mortality and disability. AIS is a serious cause of mortality and disability. Early diagnosis of atherosclerosis, which is the major cause of AIS, allows therapeutic intervention before the onset, leading to prevention of AIS. Methods: Serological identification by cDNA expression cDNA libraries and the protein array method were used for the screening of antigens recognized by serum IgG antibodies in patients with atherosclerosis. Recombinant proteins or synthetic peptides derived from candidate antigens were used as antigens to compare serum IgG levels between healthy donors (HDs) and patients with atherosclerosis-related disease using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Results: The first screening using the protein array method identified death-inducer obliterator 1 (DIDO1), forkhead box J2 (FOXJ2), and cleavage and polyadenylation specificity factor (CPSF2) as the target antigens of serum IgG antibodies in patients with AIS. Then, we prepared various antigens including glutathione S-transferase-fused DIDO1 protein as well as peptides of the amino acids 297–311 of DIDO1, 426–440 of FOXJ2, and 607–621 of CPSF2 to examine serum antibody levels. Compared with HDs, a significant increase in antibody levels of the DIDO1 protein and peptide in patients with AIS, transient ischemic attack (TIA), and chronic kidney disease (CKD) but not in those with acute myocardial infarction and diabetes mellitus (DM). Serum anti-FOXJ2 antibody levels were elevated in most patients with atherosclerosis-related diseases, whereas serum anti-CPSF2 antibody levels were associated with AIS, TIA, and DM. Receiver operating characteristic curves showed that serum DIDO1 antibody levels were highly associated with CKD, and correlation analysis revealed that serum anti-FOXJ2 antibody levels were associated with hypertension. A prospective case–control study on ischemic stroke verified that the serum antibody levels of the DIDO1 protein and DIDO1, FOXJ2, and CPSF2 peptides showed significantly higher odds ratios with a risk of AIS in patients with the highest quartile than in those with the lowest quartile, indicating that these antibody markers are useful as risk factors for AIS. Conclusions: Serum antibody levels of DIDO1, FOXJ2, and CPSF2 are useful in predicting the onset of atherosclerosis-related AIS caused by kidney failure, hypertension, and DM, respectively.

本文言語	English
論文番号	131
ジャーナル	BMC Medicine
巻	19
号	1
DOI	https://doi.org/10.1186/s12916-021-02001-9
出版ステータス	Published - 2021 12月

ASJC Scopus subject areas

医学（全般）

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1186/s12916-021-02001-9

他のファイルとリンク

引用スタイル

Hiwasa, T., Wang, H., Goto, K. I., Mine, S., Machida, T., Kobayashi, E., Yoshida, Y., Adachi, A., Matsutani, T., Sata, M., Yamagishi, K., Iso, H., Sawada, N., Tsugane, S., Kunimatsu, M., Kamitsukasa, I., Mori, M., Sugimoto, K., Uzawa, A., ... Iwadate, Y. (2021). Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 19(1), 記事 131. https://doi.org/10.1186/s12916-021-02001-9

Hiwasa, T, Wang, H, Goto, KI, Mine, S, Machida, T, Kobayashi, E, Yoshida, Y, Adachi, A, Matsutani, T, Sata, M, Yamagishi, K, Iso, H, Sawada, N, Tsugane, S, Kunimatsu, M, Kamitsukasa, I, Mori, M, Sugimoto, K, Uzawa, A, Muto, M, Kuwabara, S, Kobayashi, Y, Ohno, M, Nishi, E, Hattori, A, Yamamoto, M, Maezawa, Y, Kobayashi, K, Ishibashi, R, Takemoto, M, Yokote, K, Takizawa, H, Kishimoto, T, Matsushita, K, Kobayashi, S, Nomura, F, Arasawa, T, Kagaya, A, Maruyama, T, Matsubara, H, Tomiita, M, Hamanaka, S, Imai, Y, Nakagawa, T, Kato, N, Terada, J, Matsumura, T, Katsumata, Y, Naito, A, Tanabe, N, Sakao, S, Tatsumi, K, Ito, M, Shiratori, F, Sumazaki, M, Yajima, S, Shimada, H, Shirouzu, M, Yokoyama, S, Kudo, T, Doi, H, Iwase, K, Ashino, H, Li, SY, Kubota, M, Tomiyoshi, G, Shinmen, N, Nakamura, R, Kuroda, H & Iwadate, Y 2021, 'Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke', BMC Medicine, vol. 19, no. 1, 131. https://doi.org/10.1186/s12916-021-02001-9

@article{7e1f93485ac2499eaaf52e8d70c57a22,

title = "Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke",

abstract = "Background: Acute ischemic stroke (AIS) is a serious cause of mortality and disability. AIS is a serious cause of mortality and disability. Early diagnosis of atherosclerosis, which is the major cause of AIS, allows therapeutic intervention before the onset, leading to prevention of AIS. Methods: Serological identification by cDNA expression cDNA libraries and the protein array method were used for the screening of antigens recognized by serum IgG antibodies in patients with atherosclerosis. Recombinant proteins or synthetic peptides derived from candidate antigens were used as antigens to compare serum IgG levels between healthy donors (HDs) and patients with atherosclerosis-related disease using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Results: The first screening using the protein array method identified death-inducer obliterator 1 (DIDO1), forkhead box J2 (FOXJ2), and cleavage and polyadenylation specificity factor (CPSF2) as the target antigens of serum IgG antibodies in patients with AIS. Then, we prepared various antigens including glutathione S-transferase-fused DIDO1 protein as well as peptides of the amino acids 297–311 of DIDO1, 426–440 of FOXJ2, and 607–621 of CPSF2 to examine serum antibody levels. Compared with HDs, a significant increase in antibody levels of the DIDO1 protein and peptide in patients with AIS, transient ischemic attack (TIA), and chronic kidney disease (CKD) but not in those with acute myocardial infarction and diabetes mellitus (DM). Serum anti-FOXJ2 antibody levels were elevated in most patients with atherosclerosis-related diseases, whereas serum anti-CPSF2 antibody levels were associated with AIS, TIA, and DM. Receiver operating characteristic curves showed that serum DIDO1 antibody levels were highly associated with CKD, and correlation analysis revealed that serum anti-FOXJ2 antibody levels were associated with hypertension. A prospective case–control study on ischemic stroke verified that the serum antibody levels of the DIDO1 protein and DIDO1, FOXJ2, and CPSF2 peptides showed significantly higher odds ratios with a risk of AIS in patients with the highest quartile than in those with the lowest quartile, indicating that these antibody markers are useful as risk factors for AIS. Conclusions: Serum antibody levels of DIDO1, FOXJ2, and CPSF2 are useful in predicting the onset of atherosclerosis-related AIS caused by kidney failure, hypertension, and DM, respectively.",

keywords = "Acute ischemic stroke, Acute myocardial infarction, Antibody biomarker, Atherosclerosis, Chronic kidney disease, Diabetes mellitus",

author = "Takaki Hiwasa and Hao Wang and Goto, {Ken ichiro} and Seiichiro Mine and Toshio Machida and Eiichi Kobayashi and Yoichi Yoshida and Akihiko Adachi and Tomoo Matsutani and Mizuki Sata and Kazumasa Yamagishi and Hiroyasu Iso and Norie Sawada and Shoichiro Tsugane and Mitoshi Kunimatsu and Ikuo Kamitsukasa and Masahiro Mori and Kazuo Sugimoto and Akiyuki Uzawa and Mayumi Muto and Satoshi Kuwabara and Yoshio Kobayashi and Mikiko Ohno and Eiichiro Nishi and Akiko Hattori and Masashi Yamamoto and Yoshiro Maezawa and Kazuki Kobayashi and Ryoichi Ishibashi and Minoru Takemoto and Koutaro Yokote and Hirotaka Takizawa and Takashi Kishimoto and Kazuyuki Matsushita and Sohei Kobayashi and Fumio Nomura and Takahiro Arasawa and Akiko Kagaya and Tetsuro Maruyama and Hisahiro Matsubara and Minako Tomiita and Shinsaku Hamanaka and Yushi Imai and Tomoo Nakagawa and Naoya Kato and Jiro Terada and Takuma Matsumura and Yusuke Katsumata and Akira Naito and Nobuhiro Tanabe and Seiichiro Sakao and Koichiro Tatsumi and Masaaki Ito and Fumiaki Shiratori and Makoto Sumazaki and Satoshi Yajima and Hideaki Shimada and Mikako Shirouzu and Shigeyuki Yokoyama and Takashi Kudo and Hirofumi Doi and Katsuro Iwase and Hiromi Ashino and Li, {Shu Yang} and Masaaki Kubota and Go Tomiyoshi and Natsuko Shinmen and Rika Nakamura and Hideyuki Kuroda and Yasuo Iwadate",

note = "Funding Information: This work was supported, in part, by research grants from the Japan Science and Technology Agency (JST) in Japan, JSPS KAKENHI Grant Number 20K17953, 19K09451, 17K19810, 17K16626, 19K08596, 20K07810, 18K07387, and 16K10520, the Japan Agency for Medical Research and Development (AMED) (Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus), the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Toka-Donghua Educational and Cultural Exchange Foundation, and a grant from Setsuro Fujii Memorial, the Osaka Foundation for Promotion of Fundamental Medical Research. The serum samples used for this research were provided from the BioBank Japan Project that is supported by AMED. The Japan Public Health Center-based Prospective Study was supported by National Cancer Center Research and Development Fund (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). Funding Information: The authors would like to thank Prof. Masaki Takiguchi and Dr. Xiao-Meng Zhang (Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University) for supporting our research, as well as Masae Suzuki, Risa Kimura, Akiko Kimura, Ryo Fukushima, Yuko Ohta, Aki Furuya, and Keiko Iida for technical assistance. We also thank Dr. Takeshi Wada (Department of Internal Medicine, Chiba Aoba Municipal Hospital), Dr. Akiyo Aotsuka (Department of Internal Medicine, Chiba Aoba Municipal Hospital), Prof. Kenichiro Kitamura (Department of Internal Medicine 3, University of Yamanashi School of Medicine), Dr. Koichi Kashiwado (Department of Neurology, Kashiwado Hospital), Dr. Hideo Shin (Department of Neurosurgery, Higashi Funabashi Hospital), Dr. Takao Sugiyama (Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital), and Dr. Ryutaro Matsumura (Department of Rheumatology, National Hospital Organization, Chiba-East-Hospital) for providing research materials. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12916-021-02001-9",

language = "English",

volume = "19",

journal = "BMC Medicine",

issn = "1741-7015",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

AU - Hiwasa, Takaki

AU - Wang, Hao

AU - Goto, Ken ichiro

AU - Mine, Seiichiro

AU - Machida, Toshio

AU - Kobayashi, Eiichi

AU - Yoshida, Yoichi

AU - Adachi, Akihiko

AU - Matsutani, Tomoo

AU - Sata, Mizuki

AU - Yamagishi, Kazumasa

AU - Iso, Hiroyasu

AU - Sawada, Norie

AU - Tsugane, Shoichiro

AU - Kunimatsu, Mitoshi

AU - Kamitsukasa, Ikuo

AU - Mori, Masahiro

AU - Sugimoto, Kazuo

AU - Uzawa, Akiyuki

AU - Muto, Mayumi

AU - Kuwabara, Satoshi

AU - Kobayashi, Yoshio

AU - Ohno, Mikiko

AU - Nishi, Eiichiro

AU - Hattori, Akiko

AU - Yamamoto, Masashi

AU - Maezawa, Yoshiro

AU - Kobayashi, Kazuki

AU - Ishibashi, Ryoichi

AU - Takemoto, Minoru

AU - Yokote, Koutaro

AU - Takizawa, Hirotaka

AU - Kishimoto, Takashi

AU - Matsushita, Kazuyuki

AU - Kobayashi, Sohei

AU - Nomura, Fumio

AU - Arasawa, Takahiro

AU - Kagaya, Akiko

AU - Maruyama, Tetsuro

AU - Matsubara, Hisahiro

AU - Tomiita, Minako

AU - Hamanaka, Shinsaku

AU - Imai, Yushi

AU - Nakagawa, Tomoo

AU - Kato, Naoya

AU - Terada, Jiro

AU - Matsumura, Takuma

AU - Katsumata, Yusuke

AU - Naito, Akira

AU - Tanabe, Nobuhiro

AU - Sakao, Seiichiro

AU - Tatsumi, Koichiro

AU - Ito, Masaaki

AU - Shiratori, Fumiaki

AU - Sumazaki, Makoto

AU - Yajima, Satoshi

AU - Shimada, Hideaki

AU - Shirouzu, Mikako

AU - Yokoyama, Shigeyuki

AU - Kudo, Takashi

AU - Doi, Hirofumi

AU - Iwase, Katsuro

AU - Ashino, Hiromi

AU - Li, Shu Yang

AU - Kubota, Masaaki

AU - Tomiyoshi, Go

AU - Shinmen, Natsuko

AU - Nakamura, Rika

AU - Kuroda, Hideyuki

AU - Iwadate, Yasuo

N1 - Funding Information: This work was supported, in part, by research grants from the Japan Science and Technology Agency (JST) in Japan, JSPS KAKENHI Grant Number 20K17953, 19K09451, 17K19810, 17K16626, 19K08596, 20K07810, 18K07387, and 16K10520, the Japan Agency for Medical Research and Development (AMED) (Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus), the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Toka-Donghua Educational and Cultural Exchange Foundation, and a grant from Setsuro Fujii Memorial, the Osaka Foundation for Promotion of Fundamental Medical Research. The serum samples used for this research were provided from the BioBank Japan Project that is supported by AMED. The Japan Public Health Center-based Prospective Study was supported by National Cancer Center Research and Development Fund (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). Funding Information: The authors would like to thank Prof. Masaki Takiguchi and Dr. Xiao-Meng Zhang (Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University) for supporting our research, as well as Masae Suzuki, Risa Kimura, Akiko Kimura, Ryo Fukushima, Yuko Ohta, Aki Furuya, and Keiko Iida for technical assistance. We also thank Dr. Takeshi Wada (Department of Internal Medicine, Chiba Aoba Municipal Hospital), Dr. Akiyo Aotsuka (Department of Internal Medicine, Chiba Aoba Municipal Hospital), Prof. Kenichiro Kitamura (Department of Internal Medicine 3, University of Yamanashi School of Medicine), Dr. Koichi Kashiwado (Department of Neurology, Kashiwado Hospital), Dr. Hideo Shin (Department of Neurosurgery, Higashi Funabashi Hospital), Dr. Takao Sugiyama (Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital), and Dr. Ryutaro Matsumura (Department of Rheumatology, National Hospital Organization, Chiba-East-Hospital) for providing research materials. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Background: Acute ischemic stroke (AIS) is a serious cause of mortality and disability. AIS is a serious cause of mortality and disability. Early diagnosis of atherosclerosis, which is the major cause of AIS, allows therapeutic intervention before the onset, leading to prevention of AIS. Methods: Serological identification by cDNA expression cDNA libraries and the protein array method were used for the screening of antigens recognized by serum IgG antibodies in patients with atherosclerosis. Recombinant proteins or synthetic peptides derived from candidate antigens were used as antigens to compare serum IgG levels between healthy donors (HDs) and patients with atherosclerosis-related disease using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Results: The first screening using the protein array method identified death-inducer obliterator 1 (DIDO1), forkhead box J2 (FOXJ2), and cleavage and polyadenylation specificity factor (CPSF2) as the target antigens of serum IgG antibodies in patients with AIS. Then, we prepared various antigens including glutathione S-transferase-fused DIDO1 protein as well as peptides of the amino acids 297–311 of DIDO1, 426–440 of FOXJ2, and 607–621 of CPSF2 to examine serum antibody levels. Compared with HDs, a significant increase in antibody levels of the DIDO1 protein and peptide in patients with AIS, transient ischemic attack (TIA), and chronic kidney disease (CKD) but not in those with acute myocardial infarction and diabetes mellitus (DM). Serum anti-FOXJ2 antibody levels were elevated in most patients with atherosclerosis-related diseases, whereas serum anti-CPSF2 antibody levels were associated with AIS, TIA, and DM. Receiver operating characteristic curves showed that serum DIDO1 antibody levels were highly associated with CKD, and correlation analysis revealed that serum anti-FOXJ2 antibody levels were associated with hypertension. A prospective case–control study on ischemic stroke verified that the serum antibody levels of the DIDO1 protein and DIDO1, FOXJ2, and CPSF2 peptides showed significantly higher odds ratios with a risk of AIS in patients with the highest quartile than in those with the lowest quartile, indicating that these antibody markers are useful as risk factors for AIS. Conclusions: Serum antibody levels of DIDO1, FOXJ2, and CPSF2 are useful in predicting the onset of atherosclerosis-related AIS caused by kidney failure, hypertension, and DM, respectively.

AB - Background: Acute ischemic stroke (AIS) is a serious cause of mortality and disability. AIS is a serious cause of mortality and disability. Early diagnosis of atherosclerosis, which is the major cause of AIS, allows therapeutic intervention before the onset, leading to prevention of AIS. Methods: Serological identification by cDNA expression cDNA libraries and the protein array method were used for the screening of antigens recognized by serum IgG antibodies in patients with atherosclerosis. Recombinant proteins or synthetic peptides derived from candidate antigens were used as antigens to compare serum IgG levels between healthy donors (HDs) and patients with atherosclerosis-related disease using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Results: The first screening using the protein array method identified death-inducer obliterator 1 (DIDO1), forkhead box J2 (FOXJ2), and cleavage and polyadenylation specificity factor (CPSF2) as the target antigens of serum IgG antibodies in patients with AIS. Then, we prepared various antigens including glutathione S-transferase-fused DIDO1 protein as well as peptides of the amino acids 297–311 of DIDO1, 426–440 of FOXJ2, and 607–621 of CPSF2 to examine serum antibody levels. Compared with HDs, a significant increase in antibody levels of the DIDO1 protein and peptide in patients with AIS, transient ischemic attack (TIA), and chronic kidney disease (CKD) but not in those with acute myocardial infarction and diabetes mellitus (DM). Serum anti-FOXJ2 antibody levels were elevated in most patients with atherosclerosis-related diseases, whereas serum anti-CPSF2 antibody levels were associated with AIS, TIA, and DM. Receiver operating characteristic curves showed that serum DIDO1 antibody levels were highly associated with CKD, and correlation analysis revealed that serum anti-FOXJ2 antibody levels were associated with hypertension. A prospective case–control study on ischemic stroke verified that the serum antibody levels of the DIDO1 protein and DIDO1, FOXJ2, and CPSF2 peptides showed significantly higher odds ratios with a risk of AIS in patients with the highest quartile than in those with the lowest quartile, indicating that these antibody markers are useful as risk factors for AIS. Conclusions: Serum antibody levels of DIDO1, FOXJ2, and CPSF2 are useful in predicting the onset of atherosclerosis-related AIS caused by kidney failure, hypertension, and DM, respectively.

KW - Acute ischemic stroke

KW - Acute myocardial infarction

KW - Antibody biomarker

KW - Atherosclerosis

KW - Chronic kidney disease

KW - Diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85107427377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107427377&partnerID=8YFLogxK

U2 - 10.1186/s12916-021-02001-9

DO - 10.1186/s12916-021-02001-9

M3 - Article

C2 - 34103026

AN - SCOPUS:85107427377

SN - 1741-7015

VL - 19

JO - BMC Medicine

JF - BMC Medicine

IS - 1

M1 - 131

ER -

Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル